Haemonetics (HAE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $1.14
- Estimate
- $1.08
- Surprise
- +5.8%
- Revenue (period 2026-06-27)
- $339.4M
- Score at report (before → after)
- 5.8 → 5.6/10
Revenue source: xbrl.
How the report landed
Haemonetics (HAE) beat the $1.08 estimate with diluted EPS of $1.14 — a clear 5.8% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.8/10) to Sell at 5.6/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates HAE Sell at 4.9/10.
4 of the last 4 quarters beat the estimate; this quarter's +5.8% surprise compares with a +6.6% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: apheresis equipment from Asia
- Concentration risk — Supplier: Tetakawi
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $102.22
- Price target
- $107.38
- Stop
- $95.75
- Upside to target
- +5.0%
The stock trades at 49.7× trailing but 17.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 73 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
HAE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $4.68B
- P/E (fwd)
- 17.9
- P/E (ttm)
- 49.7
- 52-week range
- $47.32–$109.57
- Off 52-week high
- 6.7%
- RSI (14)
- 73
- Volume vs avg
- 0.04×
- Score today
- 4.9/10